Supplementary Figures 1 through 3 and Supplementary Table 1 from IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer

Fig S1: Similar level of total STAT1/3 and similar level of basal pSTAT1/3 were found in CD4 naïve T cells from healthy donors and BC patients, suggesting that the observed defective IL-6 signaling responses were not caused by lower level of total STAT1/3 or basal pSTAT1/3 in BC patients. Fig S2: Among relapsed BC patients, similar IL-6 signaling responses were found at diagnosis and at relapsed, indicating that impaired IL-6 signaling responses persistent through progression. In relapsed patients who went on to achieve remission, there was a trend towards higher IL-6 signaling in some patients. Fig S3: Lower IL-6 signaling response in peripheral CD4+ naïve T cells from melanoma (Mel), gastrointestinal (GI) and lung cancer (LC) patients. Table S1: No significant associations were found between IL-6 signaling response and clinicopathologic characteristics (age, tumor grade, T status or subtype) of BC patients.